Klein D, Sidney S, Hurley L, Iribarren C; Conference on Retroviruses and Opportunistic Infections.
Program Abstr 6th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 6th 1999 Chic Ill. 1999 Jan 31-Feb 4; 6th: 191 (abstract no. 657).
Kaiser Permanente Medical, Haywood, CA.
BACKGROUND: Protease inhibitors may alter fat metabolism resulting in higher lipid levels and increased risk for coronary heart disease (CHD). METHODS: This study is being conducted at the KPNC, a not-for-profit HMO which cares for 2.8 million people. Inpatient (IP) and outpatient (OP) diagnosis databases were scanned for CHD events (ICD9 codes 410-414) between 1/1/96 and 12/31/97 among identified HIV positive (+) Health Plan members who had no CHD events prior to baseline (later of 1/1/96, HIV diagnosis date). Person-time (through the earliest of death, Health Plan termination, CHD event or 12/31/97) and events were assigned as non-PI or as PI depending on whether they occurred before or after first PI use. Members could contribute person time to both non-PI and PI follow-up. Crude event rates per 1000 person-years (incidence densities, ID) were calculated overall and by PI status. RESULTS: 4001 HIV+ members contributed 4130 non-PI person-years (mean: 1.0 yrs) and 2101 members contributed 2287 PI person-years (mean 1.1 yrs). 57% of members contributed person-time to both non-PI and PI follow-up. There were 21 events (12 IP, 9 OP) in the absence of PI (ID: 5.1/K pyrs) and 9 events (4 IP, 5 OP) after the start of PI use (ID: 3.9/K pyrs): difference 1.2/K pyrs (95% CI: -0.6, 2.9, approximate Poisson method). The overall ID was 4.7/K pyrs. CONCLUSION: In this ongoing study, preliminary data suggest that after 1 year of follow-up, PI use does not appear to increase risk for CHD.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Coronary Disease
- HIV Infections
- HIV Seropositivity
- Humans
- Incidence
- Protease Inhibitors
Other ID:
UI: 102195422
From Meeting Abstracts